Drug Type Antibody |
Synonyms GSK 3858279, GSK3858279 |
Target |
Action antagonists |
Mechanism CCL17 antagonists(C-C motif chemokine ligand 17 antagonists) |
Active Indication |
Inactive Indication |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic peripheral neuropathic pain | Phase 2 | United States | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | China | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | Japan | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | Canada | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | France | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | Germany | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | Poland | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | South Africa | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | South Korea | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | Spain | 20 Sep 2023 |
Phase 1 | 97 | (Part A: Cohort 1: GSK3858279) | yhwmkvewee = kkbaxsdwyk mjrfsoigti (pyrcvjxvol, tkzrfrxfgc - yqqjskeqlu) View more | - | 22 Mar 2024 | ||
(Part A: Cohort 2: GSK3858279) | yhwmkvewee = pzdsyyiczo mjrfsoigti (pyrcvjxvol, xxyeumgdlr - gsezgwadep) View more | ||||||
Phase 1 | 21 | Placebo (Placebo) | qqneojriuq(yswfcskzmg) = kxvkqxwwsf grizptqwxl (lezziknkkh, dndphaotzo - rkfnwukvlh) View more | - | 01 Aug 2023 | ||
(GSK3858279 3 mg/kg IV) | qqneojriuq(yswfcskzmg) = hamrqvjviv grizptqwxl (lezziknkkh, uibmsjzhyw - vdroynqqen) View more |